Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.57 |
| ▸ | TTR | P02766 | 4/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.57 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28469484 | 0.89 | PTGS2 (0.58) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL19022422 | 0.86 | PTGS2 (0.55) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL19165155 | 0.85 | KMT2A (0.65) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| Hydrochloric Acid SCHEMBL5848951 | 0.85 | PTGS2 (0.54) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| Hydrochloric Acid SCHEMBL5848960 | 0.85 | PTGS2 (0.54) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL15308640 | 0.84 | PTGS2 (0.53) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL1042498 | 0.84 | PTGS2 (0.56) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL18380782 | 0.82 | PTGS2 (0.55) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL1044564 | 0.81 | PTGS2 (0.54) | PTGS2CYP1A1TTRCYP1B1ALOX5 | |
| SCHEMBL19022440 | 0.81 | PTGS2 (0.50) | PTGS2CYP1A1TTRCYP1B1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116034099-B | Solubilization of resveratrol glycolate and tartrate derivatives | ELC 管理有限责任公司 | 2025-04-29 | — | — | CN | claimed |
| CN-116034099-A | Solubilization of resveratrol glycolate and tartrate derivatives | ELC 管理有限责任公司 | 2023-04-28 | — | — | CN | claimed |
| EP-4165011-A1 | SOLUBIZATION OF RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES | ELC Management LLC (US) | 2023-04-19 | — | — | EP | claimed |
| WO-2021251977-A1 | SOLUBIZATION OF RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES | ELC MANAGEMENT LLC (US) | 2021-12-16 | — | — | WO | claimed |
| EP-3426626-B1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC MAN LLC (US) | 2021-07-14 | — | — | EP | claimed |
| US-10851042-B2 | Solubization of resveratrol glycolate and tartrate derivatives | ELC MANAGEMENT LLC (US) | 2020-12-01 | — | — | US | claimed |
| US-20200299223-A1 | SOLUBIZATION OF RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES | ELC MANAGEMENT LLC | 2020-09-24 | — | — | US | claimed |
| US-10717698-B2 | Resveratrol glycolate and tartrate derivatives and synthetic methods therefor | ELC MANAGEMENT LLC (US) | 2020-07-21 | — | — | US | claimed |
| US-20190071386-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC MAN LLC (US) | 2019-03-07 | — | — | US | claimed |
| EP-3426626-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC Management LLC (US) | 2019-01-16 | — | — | EP | claimed |
| WO-2017155875-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC MANAGEMENT LLC (US) | 2017-09-14 | — | — | WO | claimed |
| CN-116034099-B | Solubilization of resveratrol glycolate and tartrate derivatives | ELC 管理有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-116034099-B | Solubilization of resveratrol glycolate and tartrate derivatives | ELC 管理有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-116034099-B | Solubilization of resveratrol glycolate and tartrate derivatives | ELC 管理有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4165011-A4 | SOLUBIZATION OF RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES | ELC Management LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20190071386-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC MAN LLC (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3426626-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC Management LLC (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3426626-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC Management LLC (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155875-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC MANAGEMENT LLC (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155875-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | ELC MANAGEMENT LLC (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851042-B2 | Solubization of resveratrol glycolate and tartrate derivatives | GRHPR, SORD, SUCNR1 | PTGS2 3496/4885CYP1A1 2079/4885TTR 28/4885 |
| US-10717698-B2 | Resveratrol glycolate and tartrate derivatives and synthetic methods therefor | GRHPR, SUCNR1, TECR | PTGS2 3441/4885CYP1A1 2283/4885TTR 1497/4885 |
| US-20200299223-A1 | SOLUBIZATION OF RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES | SORD, GRHPR, SUCNR1 | PTGS2 3434/4885CYP1A1 3054/4885TTR 65/4885 |
| US-20190071386-A1 | RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR | GRHPR, HMGCR, SUCNR1 | PTGS2 2897/4885CYP1A1 2464/4885TTR 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.